Ertumaxomab

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameErtumaxomab
Drug Alias Name厄妥索单抗RexomabRexomun
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionImmunostimulantsApoptosis stimulants
TargetsT cell surface glycoprotein CD3Receptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancerBreast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTrion PharmaNeopharm
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKrankenhaus Nordwest GmbhNeovii Biotech Gmbh
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancerBreast NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia